Foley Hoag provided IP due diligence counsel to Genmab A/S (NASDAQ: GMAB), an international biotech company specializing in antibody therapeutics for the treatment of cancer and other serious diseases, on its proposed $8 billion acquisition of Merus N.V., a clinical-stage biotechnology company.
The proposed acquisition of Merus, with its late-stage breakthrough therapy asset petosemtamab, will enable Genmab to accelerate its shift to a wholly owned model and drive sustained growth and innovation.
The Foley Hoag team was led by Amy Baker Mandragouras and included Ariana Harris, Erin Foley, Sammi Devenport, Jordan Isaacs, Kimberlee Hixon, and Carolyn Blake.
Learn more about the transaction
here.
